ESTIMATING THE COST TO SOCIETY FOR EXENATIDE QW AND INSULIN GLARGINE IN THE UNITED STATES FOR THE TREATMENT OF TYPE 2 DIABETES
May 1, 2016, 00:00 AM
10.1016/j.jval.2016.03.1288
https://www.valueinhealthjournal.com/article/S1098-3015(16)01356-5/fulltext
Section Title :
Diabetes/Endocrine Disorders - Cost Studies
Section Order :
631
First Page :
A201
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)01356-5&doi=10.1016/j.jval.2016.03.1288